Table of Contents
- What is LY3540378?
- What condition does LY3540378 target?
- How does LY3540378 work?
- Current Clinical Trial
- Who can participate in the trial?
- How is LY3540378 administered?
- Potential Benefits of LY3540378
What is LY3540378?
LY3540378 is a new medication being developed by Eli Lilly and Company for the treatment of chronic heart failure with preserved ejection fraction (HFpEF). It is currently undergoing clinical trials to assess its safety and effectiveness.[1]
The scientific name of this drug is quite complex: IGG against serum albumin fused with relaxin 2, chain B (2-29) and relaxin 2 (chain A). This long name describes the structure of the medication, which is a combination of different proteins designed to target specific aspects of heart function.[1]
What condition does LY3540378 target?
LY3540378 is being developed to treat chronic heart failure with preserved ejection fraction (HFpEF). This is a type of heart failure where the heart muscle pumps normally, but the heart doesn’t fill with blood properly between beats. This leads to less blood being pumped out to the body.[1]
HFpEF can cause symptoms such as:
- Shortness of breath
- Fatigue
- Swelling in the legs and ankles
- Difficulty exercising
How does LY3540378 work?
While the exact mechanism of LY3540378 is not fully described in the available information, we can infer some details based on its structure:
- IGG (Immunoglobulin G): This is an antibody that can target specific proteins in the body.
- Serum albumin: This is a protein that helps maintain fluid balance in the body and can prolong the action of medications.
- Relaxin 2: This is a hormone that can help improve blood flow and reduce stiffness in blood vessels and the heart.
By combining these elements, LY3540378 may help improve heart function in patients with HFpEF, potentially by reducing stiffness in the heart and improving blood flow.[1]
Current Clinical Trial
LY3540378 is currently being studied in a Phase 2 clinical trial. This trial is designed to investigate the efficacy and safety of the drug in adults with worsening chronic HFpEF.[1]
Key details of the trial include:
- It is a randomized, double-blind, placebo-controlled study. This means that participants are randomly assigned to receive either LY3540378 or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study.
- The main objective is to demonstrate that LY3540378 is superior to placebo in improving atrial myopathy (a condition affecting the upper chambers of the heart) in participants with worsening chronic HFpEF.
- The primary endpoint (main measure of success) is the change from baseline in Left Atrial Reservoir Strain (LARS). This is a measure of how well the left upper chamber of the heart (left atrium) functions.[1]
Who can participate in the trial?
The trial has specific criteria for who can and cannot participate:
Inclusion criteria:
- Participants must have chronic heart failure[1]
Exclusion criteria:
- Participants cannot have had a heart transplant
- Participants cannot have uncontrolled irregular heart beats
- Participants cannot have heart failure triggered by a blood clot in the lungs[1]
How is LY3540378 administered?
LY3540378 is administered as a solution for injection. The trial information indicates that it is given through subcutaneous (SC) injection, which means it is injected just under the skin.[1]
Potential Benefits of LY3540378
While the full benefits of LY3540378 are still being studied, the researchers hope that it will:
- Improve heart function in patients with HFpEF
- Reduce symptoms associated with heart failure
- Improve quality of life for patients with this condition
- Potentially slow the progression of heart failure
It’s important to note that as this drug is still in clinical trials, its benefits and potential side effects are not yet fully known. Patients should always consult with their healthcare providers about the latest treatment options for their specific condition.[1]
